Objective:To investigate the clinical value of human papiiloma virus E6/E7 mRNA by branch－DNA technology.Methods:In the exfoliated cervical cells form 167 women of cervical cancer screening by liquid based thinprep cytology test(TCT),branch－DNA(bDNA) technology was performed to examine the HPV－E6/E7 mRNA. The HPV－E6/E7 DNA was also examined in 43 cases at the same time. Results:①The copies of HPV－E6/E7 mRNA are positively related with HPV－E6/E7 DNA(r = 0.465,P = 0.002);②The HPV－E6/E7 mRNA positive rate was 43.1% in all groups. The HPV－E6/E7 mRNA positive rate and copies were increased along with the increase of the grade of cervical lesions(χ2 = 41.396,P < 0.001; H = 39.350,P < 0.001);③The sensitivity,specificity,accuracy,positive predictive value,negative predictive value of HPV－E6/E7 mRNA for LSIL+ were 67.1% (95%CI,56.1% to 78.1%),74.2%(95%CI,65.5% to 82.9%),71.3%(95%CI,64.4% to 78.1%),65.3%(95%CI,54.3% to 76.3%) and 75.8% (95%CI,67.2% to 84.4%),respectively. Conclusion:The HPV－E6/E7 mRNA was related with the type of cervix cytology,and had high efficiency diagnose for LSIL+. The HPV－E6/E7 mRNA can be applied for risk assessment of cervical cancer.